NYLIM
MRNA icon

New York Life Investment Management’s Moderna MRNA Stock Holding History

New York Life Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.39M Sell
91,235
-7,248
-7% -$375K 0.04% 303
2026
Q1 		$5M Buy
98,483
+18,353
+23% +$856K 0.04% 330
2025
Q4 		$2.36M Sell
80,130
-721
-0.9% -$19.6K 0.02% 497
2025
Q3 		$2.09M Sell
80,851
-3,574
-4% -$99.7K 0.02% 535
2025
Q2 		$2.33M Buy
84,425
+31,327
+59% +$825K 0.02% 503
2025
Q1 		$1.51M Buy
53,098
+81
+0.2% +$2.87K 0.02% 583
2024
Q4 		$2.2M Buy
53,017
+6,609
+14% +$316K 0.02% 533
2024
Q3 		$3.1M Sell
46,408
-108
-0.2% -$9.92K 0.03% 466
2024
Q2 		$5.52M Buy
46,516
+313
+0.7% +$39.6K 0.06% 310
2024
Q1 		$4.92M Sell
46,203
-1,906
-4% -$192K 0.05% 343
2023
Q4 		$4.78M Buy
48,109
+67
+0.1% +$5.63K 0.05% 337
2023
Q3 		$4.96M Buy
48,042
+639
+1% +$71.3K 0.05% 309
2023
Q2 		$5.76M Buy
47,403
+173
+0.4% +$23.1K 0.06% 287
2023
Q1 		$7.25M Buy
47,230
+253
+0.5% +$41.7K 0.08% 252
2022
Q4 		$8.44M Sell
46,977
-832
-2% -$136K 0.1% 223
2022
Q3 		$5.65M Sell
47,809
-1,213
-2% -$184K 0.07% 281
2022
Q2 		$7M Buy
+49,022
New +$7.01M 0.08% 253

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

New York Life Investment Management's MRNA Position: Q2 2026 in Review

New York Life Investment Management reduced its Moderna (MRNA) stake by 7.4% in Q2 2026, selling an estimated $375K and leaving 91,235 shares worth $6.39M. The position accounts for 0.04% of the portfolio, ranked #303.

New York Life Investment Management first reported a position in MRNA in Q2 2022 and has held it in 17 quarters since. The position peaked at $8.44M in Q4 2022. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • New York Life Investment Management held 91,235 shares of Moderna worth $6.39M as of Q2 2026.
  • New York Life Investment Management sold 7,248 Moderna shares in Q2 2026, an estimated $375K.
  • Moderna made up 0.04% of New York Life Investment Management's portfolio in Q2 2026, its #303 holding.
  • New York Life Investment Management first reported a position in Moderna in Q2 2022 and has held it in 17 quarters since.
  • New York Life Investment Management's Moderna position peaked at $8.44M in Q4 2022.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.